スペシャリティ医薬品流通市場：適応疾患別、流通業者タイプ別、流通タイプ別、エンドユーザー別-2025年～2030年世界予測

特殊医薬品流通市場の2023年の市場規模は47億6,000万米ドルで、2024年には54億7,000万米ドルに達すると予測され、CAGR 14.44％で成長し、2030年には122億5,000万米ドルに達すると予測されています。

特殊医薬品流通市場は主に、高コストで特定の保管や投与が必要な医薬品など、包括的な取り扱いを必要とする特殊な医薬品の供給と管理に関わる。このような医薬品には、がん、HIV、多発性硬化症などの慢性疾患の治療が含まれ、多くの場合、個別の流通チャネルが必要となります。特殊医薬品流通の必要性は、個別化医療に対する需要の高まりと、複雑な物流を管理し潜在的な障害から保護できる革新的な送達システムの必要性によって強調されています。用途別に見ると、この市場は必要な医薬品を効率的かつ安全に提供することで薬局、病院、診療所をサポートし、患者は最適な健康結果を保証する専門的な治療レジメンから利益を得ることができます。この流通モデルは、主にヘルスケア部門に貢献しており、公的機関や民間企業の両方に影響を及ぼしています。

ブロックチェーンやIoTのような革新的技術がサプライチェーンの安全性と透明性を高めており、市場拡大の主な要因として生物製剤と遺伝子治療の急成長が指摘されています。患者中心のケアモデルが重視されることで、宅配サービスやバリューベースの取り決めの機会が拡大し、新たな成長機会がもたらされます。しかし、規制の複雑さ、特殊医薬品の高コスト、償還の問題などの課題が大きな障害となり、市場のダイナミクスに影響を及ぼす可能性があります。農村部ではインフラが限られているため、効率的な流通がさらに阻害される可能性があります。

こうした課題を克服するため、業界はデジタルヘルスプラットフォームとデータ分析に投資し、サプライチェーンの最適化と患者エンゲージメントの強化を図る必要があります。コールドチェーン・ロジスティクスと自動化における革新は、間接費を大幅に削減し、流通効率を向上させることができます。急速な技術進歩や厳しい規制環境を特徴とする市場の性質上、新技術の採用や利害関係者間の協力関係の醸成に積極的に取り組む必要があります。製剤やデリバリー・メカニズムにおけるイノベーションを促進し、ハイテク企業との戦略的パートナーシップを組み合わせることで、課題を効果的に克服する能力が強化され、特殊医薬品流通市場における持続可能性と競争優位性が確保されるであろう。

市場力学：急速に進化する特殊医薬品流通市場における重要な市場洞察の解明

特殊医薬品流通市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 特殊医薬品の開発パイプラインと取引の増加
  • 患者中心の医療を提供するための薬剤コスト、供給、保管の最適化の重視
• 市場抑制要因
  • さまざまな流通チャネルの管理における複雑さ
• 市場機会
  • 新技術の統合と特殊医薬品流通の進歩
  • 世界の専門薬局の拡大
• 市場の課題
  • 専門薬の取り扱いに関連する規制枠組みの変化

ポーターの5つの力：特殊医薬品流通市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：特殊医薬品流通市場における外部からの影響の把握

外部マクロ環境要因は、特殊医薬品流通市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析特殊医薬品流通市場における競合情勢の把握

特殊医薬品流通市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス特殊医薬品流通市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、特殊医薬品流通市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限はベンダーを明確かつ正確に区分し、ユーザーが戦略目標に最適なパートナーやソリューションを特定するのに役立ちます。

本レポートは、主要な注目分野を網羅した包括的な市場分析を提供しています：

1.市場の浸透度：業界主要企業の広範なデータを含む、現在の市場環境の詳細なレビュー。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 専門医薬品の開発パイプラインと取引の増加
    • 患者中心のケアを提供するために、薬剤コスト、供給、保管の最適化に重点を置く
  • 抑制要因
    • さまざまな流通チャネルの管理の複雑さ
  • 機会
    • 特殊医薬品流通における新しいテクノロジーの統合と進歩
    • 世界中で専門薬局の拡大が進む
  • 課題
    • 特殊医薬品の取り扱いに関連する規制枠組みの変更
• 市場セグメンテーション分析
  • 疾患適応症：腫瘍疾患の治療における専門薬の需要の高まり
  • 販売業者タイプ：専門医薬品のフルライン卸売業者の存在感が高まっている
  • 流通形態：専門薬局への浸透度が高い
  • エンドユーザー：家庭環境における特殊医薬品流通の新たな可能性
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 特殊医薬品流通市場：適応疾患別

• エイズ
• 血友病
• 多発性硬化症
• 腫瘍学
• 関節リウマチ

第7章 特殊医薬品流通市場：流通業者タイプ別

• フルライン卸売業者
• 専門販売業者

第8章 特殊医薬品流通市場：流通タイプ別

• 病院・クリニック薬局
• 独立薬局
• 大手チェーン薬局
• 通信販売薬局
• オンラインストア
• 専門薬局

第9章 特殊医薬品流通市場：エンドユーザー別

• 外来手術センター
• ヘルスケア支払者
• ホーム設定
• 病院・クリニック

第10章 南北アメリカの特殊医薬品流通市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋の特殊医薬品流通市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの特殊医薬品流通市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
  • FFF Enterprisesは、伝染性軟属腫の初のFDA承認治療であるYCANTHの独占販売代理店としてVerrica Pharmaceuticalsとの提携を発表
  • オルシーニ専門薬局が、CHAPLE病の初かつ唯一の治療であるVEOPOZ（ポゼリマブ-BBFG）の独占専門薬局パートナーに選定されました。
  • MedisとESTEVEがCEE10カ国で販売契約を締結
  • エベレスト・メディシンズ、中国本土でのXERAVAの商業化を加速するため上海製薬子会社との戦略的提携を発表
  • エレバンス・ヘルス、バイオプラス買収の完了を発表
  • CVSヘルスがオークストリートヘルスを買収
  • Shields Health SolutionsとMyMichigan Healthが提携し、患者と家族向けの専門薬局サービスを強化
  • シールズ・ヘルス・ソリューションズ、全国規模のパートナーシップを拡大し、専門薬局サービスの向上を目指す
  • プライム・セラピューティクス、13億5,000万米ドルのマゼランRx買収を完了、薬局と医療用医薬品管理の専門知識を統合
  • マッケソン・カナダ、専門患者の治療成果を簡素化し強化する新しいデジタルエコシステムを発表
  • マニュライフとショッパーズドラッグマートが協力し、深刻な病状の管理を支援
  • マーケン、セドラ・エクスプレスの医療用宅配事業を買収することで合意、ニュージーランドでの直接展開を拡大
  • カーディナルヘルス、在宅ソリューション事業の拡大を継続
  • ハロザイム、アンタレス・ファーマを約9億6,000万米ドルで買収へ

企業一覧

• Shanghai Pharmaceuticals Group Co., Ltd.
• CVS Specialty, Inc. by CVS Health Corporation
• AmerisourceBergen Corporation
• China National Pharmaceutical Group Corporation
• Teva Pharmaceutical Industries Ltd.
• McKesson Corporation
• Suzuken Co., Ltd.
• Eversana
• PHOENIX Pharmahandel GmbH & Co KG
• Accredo Health Group, Inc.
• Lifeline Pharmaceuticals, LLC
• Aark Pharmaceuticals
• Optum, Inc.
• Feron Healthcare Pvt Ltd.
• Morris & Dickson Co., LLC
• Medipal Holdings Corporation
• Kroger Specialty Pharmacy
• Walmart Inc.
• Elevance Health, Inc.
• FFF Enterprises Inc.
• Cardinal Health, Inc.
• Shields Health Solutions Holdings, LLC
• Medis Intago, d.o.o.
• Marken by United Parcel Service, Inc.
• Centene Corporation
• Sun Pharmaceutical Industries Limited
• BioCare, Inc.

LIST OF FIGURES

• FIGURE 1. SPECIALTY DRUG DISTRIBUTION MARKET RESEARCH PROCESS
• FIGURE 2. SPECIALTY DRUG DISTRIBUTION MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL SPECIALTY DRUG DISTRIBUTION MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTOR TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTOR TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTION TYPE, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTION TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. SPECIALTY DRUG DISTRIBUTION MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. SPECIALTY DRUG DISTRIBUTION MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. SPECIALTY DRUG DISTRIBUTION MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL SPECIALTY DRUG DISTRIBUTION MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. SPECIALTY DRUG DISTRIBUTION MARKET DYNAMICS
• TABLE 7. GLOBAL SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY AIDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY HEMOPHILIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY FULL LINE WHOLESALERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY SPECIALTY DISTRIBUTORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTION TYPE, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY HOSPITALS & CLINIC PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY LARGE CHAIN PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY MAIL-ORDER PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY ONLINE STORES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY HEALTHCARE PAYERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY HOME SETTINGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY HOSPITAL & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTION TYPE, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTION TYPE, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 37. BRAZIL SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 38. BRAZIL SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 39. BRAZIL SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTION TYPE, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 41. CANADA SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 42. CANADA SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 43. CANADA SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTION TYPE, 2018-2030 (USD MILLION)
• TABLE 44. CANADA SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 45. MEXICO SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 46. MEXICO SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 47. MEXICO SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTION TYPE, 2018-2030 (USD MILLION)
• TABLE 48. MEXICO SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 49. UNITED STATES SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 50. UNITED STATES SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 51. UNITED STATES SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTION TYPE, 2018-2030 (USD MILLION)
• TABLE 52. UNITED STATES SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 53. UNITED STATES SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 54. ASIA-PACIFIC SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 55. ASIA-PACIFIC SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 56. ASIA-PACIFIC SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTION TYPE, 2018-2030 (USD MILLION)
• TABLE 57. ASIA-PACIFIC SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 58. ASIA-PACIFIC SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 59. AUSTRALIA SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 60. AUSTRALIA SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 61. AUSTRALIA SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTION TYPE, 2018-2030 (USD MILLION)
• TABLE 62. AUSTRALIA SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 63. CHINA SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 64. CHINA SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 65. CHINA SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTION TYPE, 2018-2030 (USD MILLION)
• TABLE 66. CHINA SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 67. INDIA SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 68. INDIA SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 69. INDIA SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTION TYPE, 2018-2030 (USD MILLION)
• TABLE 70. INDIA SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 71. INDONESIA SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 72. INDONESIA SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 73. INDONESIA SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTION TYPE, 2018-2030 (USD MILLION)
• TABLE 74. INDONESIA SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 75. JAPAN SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 76. JAPAN SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 77. JAPAN SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTION TYPE, 2018-2030 (USD MILLION)
• TABLE 78. JAPAN SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 79. MALAYSIA SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 80. MALAYSIA SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 81. MALAYSIA SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTION TYPE, 2018-2030 (USD MILLION)
• TABLE 82. MALAYSIA SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 83. PHILIPPINES SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 84. PHILIPPINES SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 85. PHILIPPINES SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTION TYPE, 2018-2030 (USD MILLION)
• TABLE 86. PHILIPPINES SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 87. SINGAPORE SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 88. SINGAPORE SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 89. SINGAPORE SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTION TYPE, 2018-2030 (USD MILLION)
• TABLE 90. SINGAPORE SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 91. SOUTH KOREA SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 92. SOUTH KOREA SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 93. SOUTH KOREA SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTION TYPE, 2018-2030 (USD MILLION)
• TABLE 94. SOUTH KOREA SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 95. TAIWAN SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 96. TAIWAN SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 97. TAIWAN SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTION TYPE, 2018-2030 (USD MILLION)
• TABLE 98. TAIWAN SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 99. THAILAND SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 100. THAILAND SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 101. THAILAND SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTION TYPE, 2018-2030 (USD MILLION)
• TABLE 102. THAILAND SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 103. VIETNAM SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 104. VIETNAM SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 105. VIETNAM SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTION TYPE, 2018-2030 (USD MILLION)
• TABLE 106. VIETNAM SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 107. EUROPE, MIDDLE EAST & AFRICA SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 108. EUROPE, MIDDLE EAST & AFRICA SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 109. EUROPE, MIDDLE EAST & AFRICA SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTION TYPE, 2018-2030 (USD MILLION)
• TABLE 110. EUROPE, MIDDLE EAST & AFRICA SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 111. EUROPE, MIDDLE EAST & AFRICA SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 112. DENMARK SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 113. DENMARK SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 114. DENMARK SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTION TYPE, 2018-2030 (USD MILLION)
• TABLE 115. DENMARK SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 116. EGYPT SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 117. EGYPT SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 118. EGYPT SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTION TYPE, 2018-2030 (USD MILLION)
• TABLE 119. EGYPT SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 120. FINLAND SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 121. FINLAND SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 122. FINLAND SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTION TYPE, 2018-2030 (USD MILLION)
• TABLE 123. FINLAND SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 124. FRANCE SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 125. FRANCE SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 126. FRANCE SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTION TYPE, 2018-2030 (USD MILLION)
• TABLE 127. FRANCE SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 128. GERMANY SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 129. GERMANY SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 130. GERMANY SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTION TYPE, 2018-2030 (USD MILLION)
• TABLE 131. GERMANY SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 132. ISRAEL SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 133. ISRAEL SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 134. ISRAEL SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTION TYPE, 2018-2030 (USD MILLION)
• TABLE 135. ISRAEL SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 136. ITALY SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 137. ITALY SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 138. ITALY SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTION TYPE, 2018-2030 (USD MILLION)
• TABLE 139. ITALY SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 140. NETHERLANDS SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 141. NETHERLANDS SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 142. NETHERLANDS SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTION TYPE, 2018-2030 (USD MILLION)
• TABLE 143. NETHERLANDS SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 144. NIGERIA SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 145. NIGERIA SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 146. NIGERIA SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTION TYPE, 2018-2030 (USD MILLION)
• TABLE 147. NIGERIA SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 148. NORWAY SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 149. NORWAY SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 150. NORWAY SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTION TYPE, 2018-2030 (USD MILLION)
• TABLE 151. NORWAY SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 152. POLAND SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 153. POLAND SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 154. POLAND SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTION TYPE, 2018-2030 (USD MILLION)
• TABLE 155. POLAND SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 156. QATAR SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 157. QATAR SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 158. QATAR SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTION TYPE, 2018-2030 (USD MILLION)
• TABLE 159. QATAR SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 160. RUSSIA SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 161. RUSSIA SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 162. RUSSIA SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTION TYPE, 2018-2030 (USD MILLION)
• TABLE 163. RUSSIA SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 164. SAUDI ARABIA SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 165. SAUDI ARABIA SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 166. SAUDI ARABIA SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTION TYPE, 2018-2030 (USD MILLION)
• TABLE 167. SAUDI ARABIA SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 168. SOUTH AFRICA SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 169. SOUTH AFRICA SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 170. SOUTH AFRICA SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTION TYPE, 2018-2030 (USD MILLION)
• TABLE 171. SOUTH AFRICA SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 172. SPAIN SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 173. SPAIN SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 174. SPAIN SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTION TYPE, 2018-2030 (USD MILLION)
• TABLE 175. SPAIN SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 176. SWEDEN SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 177. SWEDEN SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 178. SWEDEN SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTION TYPE, 2018-2030 (USD MILLION)
• TABLE 179. SWEDEN SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 180. SWITZERLAND SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 181. SWITZERLAND SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 182. SWITZERLAND SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTION TYPE, 2018-2030 (USD MILLION)
• TABLE 183. SWITZERLAND SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 184. TURKEY SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 185. TURKEY SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 186. TURKEY SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTION TYPE, 2018-2030 (USD MILLION)
• TABLE 187. TURKEY SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 188. UNITED ARAB EMIRATES SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 189. UNITED ARAB EMIRATES SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 190. UNITED ARAB EMIRATES SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTION TYPE, 2018-2030 (USD MILLION)
• TABLE 191. UNITED ARAB EMIRATES SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 192. UNITED KINGDOM SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 193. UNITED KINGDOM SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 194. UNITED KINGDOM SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY DISTRIBUTION TYPE, 2018-2030 (USD MILLION)
• TABLE 195. UNITED KINGDOM SPECIALTY DRUG DISTRIBUTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 196. SPECIALTY DRUG DISTRIBUTION MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 197. SPECIALTY DRUG DISTRIBUTION MARKET, FPNV POSITIONING MATRIX, 2023

The Specialty Drug Distribution Market was valued at USD 4.76 billion in 2023, expected to reach USD 5.47 billion in 2024, and is projected to grow at a CAGR of 14.44%, to USD 12.25 billion by 2030.

The specialty drug distribution market primarily involves the supply and management of specialized pharmaceuticals that require comprehensive handling, including drugs with high costs and specific storage or administration needs. These include treatments for chronic diseases such as cancer, HIV, and multiple sclerosis, often necessitating a tailored distribution channel. The necessity of specialty drug distribution is underscored by the growing demand for personalized medicine and the need for innovative delivery systems that can manage complex logistics and safeguard against potential disruptions. Application-wise, the market supports pharmacies, hospitals, and clinics by providing necessary drugs efficiently and safely, while patients benefit from specialized therapeutic regimens ensuring optimal health outcomes. This distribution model predominantly serves the healthcare sector, influencing both public and private entities.

Recent market insights point to the burgeoning growth of biologics and gene therapies as primary factors driving market expansion, with innovative technologies like blockchain and IoT enhancing supply chain security and transparency. The emphasis on patient-centric care models expands opportunities for home delivery services and value-based arrangements, providing new avenues for growth. However, challenges such as regulatory complexities, high costs of specialty drugs, and reimbursement issues pose significant obstacles, potentially affecting market dynamics. Limited infrastructure in rural areas may further hinder efficient distribution.

To surmount these challenges, the industry should invest in digital health platforms and data analytics to optimize supply chains and enhance patient engagement. Innovations in cold chain logistics and automation can significantly reduce overhead costs and improve distribution efficacy. The market's nature, characterized by rapid technological advancement and stringent regulatory environments, necessitates a proactive approach in adopting emerging technologies and fostering collaborations between stakeholders. Encouraging innovation in drug formulation and delivery mechanisms, combined with strategic partnerships with tech firms, will bolster the capacity to navigate challenges effectively, ensuring sustainability and competitive advantage in the specialty drug distribution market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Specialty Drug Distribution Market

The Specialty Drug Distribution Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing specialty drug development pipeline and trade
  • Emphasis on drug cost, supply, and storage optimization to offer patient-centric care
• Market Restraints
  • Complexity in managing different distribution channels
• Market Opportunities
  • New technology integration and advancements in specialty drug distribution
  • Rising expansion of specialty pharmacies worldwide
• Market Challenges
  • Changing regulatory frameworks associated with specialty drug handling

Porter's Five Forces: A Strategic Tool for Navigating the Specialty Drug Distribution Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Specialty Drug Distribution Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Specialty Drug Distribution Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Specialty Drug Distribution Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Specialty Drug Distribution Market

A detailed market share analysis in the Specialty Drug Distribution Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Specialty Drug Distribution Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Specialty Drug Distribution Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Specialty Drug Distribution Market, highlighting leading vendors and their innovative profiles. These include Shanghai Pharmaceuticals Group Co., Ltd., CVS Specialty, Inc. by CVS Health Corporation, AmerisourceBergen Corporation, China National Pharmaceutical Group Corporation, Teva Pharmaceutical Industries Ltd., McKesson Corporation, Suzuken Co., Ltd., Eversana, PHOENIX Pharmahandel GmbH & Co KG, Accredo Health Group, Inc., Lifeline Pharmaceuticals, LLC, Aark Pharmaceuticals, Optum, Inc., Feron Healthcare Pvt Ltd., Morris & Dickson Co., LLC, Medipal Holdings Corporation, Kroger Specialty Pharmacy, Walmart Inc., Elevance Health, Inc., FFF Enterprises Inc., Cardinal Health, Inc., Shields Health Solutions Holdings, LLC, Medis Intago, d.o.o., Marken by United Parcel Service, Inc., Centene Corporation, Sun Pharmaceutical Industries Limited, and BioCare, Inc..

Market Segmentation & Coverage

This research report categorizes the Specialty Drug Distribution Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Disease Indication, market is studied across AIDS, Hemophilia, Multiple Sclerosis, Oncology, and Rheumatoid Arthritis.
• Based on Distributor Type, market is studied across Full line Wholesalers and Specialty Distributors.
• Based on Distribution Type, market is studied across Hospitals & Clinic Pharmacies, Independent Pharmacies, Large Chain Pharmacies, Mail-Order Pharmacies, Online Stores, and Specialty Pharmacies.
• Based on End-User, market is studied across Ambulatory Surgical Centers, Healthcare Payers, Home Settings, and Hospital & Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing specialty drug development pipeline and trade
    • 5.1.1.2. Emphasis on drug cost, supply, and storage optimization to offer patient-centric care
  • 5.1.2. Restraints
    • 5.1.2.1. Complexity in managing different distribution channels
  • 5.1.3. Opportunities
    • 5.1.3.1. New technology integration and advancements in specialty drug distribution
    • 5.1.3.2. Rising expansion of specialty pharmacies worldwide
  • 5.1.4. Challenges
    • 5.1.4.1. Changing regulatory frameworks associated with specialty drug handling
• 5.2. Market Segmentation Analysis
  • 5.2.1. Disease Indication: Escalated need of specialty drugs to treat oncology conditions
  • 5.2.2. Distributor Type: Rising presence of full line wholesalers of speciality drugs
  • 5.2.3. Distribution Type: Significant penetration in specialty pharmacies
  • 5.2.4. End-User: Emerging potential for specialty drug distribution in home settings
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Specialty Drug Distribution Market, by Disease Indication

• 6.1. Introduction
• 6.2. AIDS
• 6.3. Hemophilia
• 6.4. Multiple Sclerosis
• 6.5. Oncology
• 6.6. Rheumatoid Arthritis

7. Specialty Drug Distribution Market, by Distributor Type

• 7.1. Introduction
• 7.2. Full line Wholesalers
• 7.3. Specialty Distributors

8. Specialty Drug Distribution Market, by Distribution Type

• 8.1. Introduction
• 8.2. Hospitals & Clinic Pharmacies
• 8.3. Independent Pharmacies
• 8.4. Large Chain Pharmacies
• 8.5. Mail-Order Pharmacies
• 8.6. Online Stores
• 8.7. Specialty Pharmacies

9. Specialty Drug Distribution Market, by End-User

• 9.1. Introduction
• 9.2. Ambulatory Surgical Centers
• 9.3. Healthcare Payers
• 9.4. Home Settings
• 9.5. Hospital & Clinics

10. Americas Specialty Drug Distribution Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Specialty Drug Distribution Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Specialty Drug Distribution Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. FFF Enterprises Announces its Partnership with Verrica Pharmaceuticals to be the Exclusive Distributor of YCANTH, the First FDA Approved Treatment for Molluscum Contagiosum
  • 13.3.2. Orsini Specialty Pharmacy Selected to be the Exclusive Specialty Pharmacy Partner for VEOPOZ (pozelimab-bbfg), the First and Only Treatment for CHAPLE Disease
  • 13.3.3. Medis and ESTEVE Signed a Distribution Agreement for 10 CEE Countries
  • 13.3.4. Everest Medicines Announces Strategic Partnership with Shanghai Pharma Subsidiary to Accelerate the Commercialization of XERAVA in Mainland China
  • 13.3.5. Elevance Health Announces Closing of BioPlus Acquisition
  • 13.3.6. CVS Health to acquire Oak Street Health
  • 13.3.7. Shields Health Solutions and MyMichigan Health Partner to Enhance Specialty Pharmacy Services for Patients and Families
  • 13.3.8. Shields Health Solutions Expands Nationwide Partnerships to Enhance Specialty Pharmacy Services
  • 13.3.9. Prime Therapeutics Closes USD 1.35 Billion Magellan Rx Acquisition, Uniting Pharmacy and Medical Drug Management Expertise
  • 13.3.10. McKesson Canada Launches New Digital Ecosystem to Simplify and Enhance Specialty Patient Outcomes
  • 13.3.11. Manulife and Shoppers Drug Mart Collaborate to Help Manage Serious Medical Conditions
  • 13.3.12. Marken Reaches Agreement to Acquire the Medical Courier Business of Cedra Express, Expands Direct Presence in New Zealand
  • 13.3.13. Cardinal Health Continues to Expand at-Home Solutions Business
  • 13.3.14. Halozyme to Acquire Antares Pharma for Around USD 960 Million

Companies Mentioned

• 1. Shanghai Pharmaceuticals Group Co., Ltd.
• 2. CVS Specialty, Inc. by CVS Health Corporation
• 3. AmerisourceBergen Corporation
• 4. China National Pharmaceutical Group Corporation
• 5. Teva Pharmaceutical Industries Ltd.
• 6. McKesson Corporation
• 7. Suzuken Co., Ltd.
• 8. Eversana
• 9. PHOENIX Pharmahandel GmbH & Co KG
• 10. Accredo Health Group, Inc.
• 11. Lifeline Pharmaceuticals, LLC
• 12. Aark Pharmaceuticals
• 13. Optum, Inc.
• 14. Feron Healthcare Pvt Ltd.
• 15. Morris & Dickson Co., LLC
• 16. Medipal Holdings Corporation
• 17. Kroger Specialty Pharmacy
• 18. Walmart Inc.
• 19. Elevance Health, Inc.
• 20. FFF Enterprises Inc.
• 21. Cardinal Health, Inc.
• 22. Shields Health Solutions Holdings, LLC
• 23. Medis Intago, d.o.o.
• 24. Marken by United Parcel Service, Inc.
• 25. Centene Corporation
• 26. Sun Pharmaceutical Industries Limited
• 27. BioCare, Inc.